{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Dizziness"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Fatigue (asthenia, lethargy, malaise)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Inf (clin/microbio) w/Gr 3-4 neuts - Eye NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Inf (clin/microbio) w/Gr 3-4 neuts - Lung"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Infection with unknown ANC - Urinary tract NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Mood alteration - agitation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Mood alteration - anxiety"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Muscle weakness, not d/t neuropathy - body/general"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Neuropathy: motor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Neuropathy: sensory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Pain - Bone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Pain - Joint"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Phosphate, serum-low (hypophosphatemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Sodium, serum-low (hyponatremia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Thrombosis/thrombus/embolism"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.","groups":[{"description":"Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 2 cycles","id":"OG000","title":"Initial ABVD"},{"description":"Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 4 cycles","id":"OG001","title":"PET-negative: Continued ABVD"},{"description":"Etoposide 100 mg/m\\^2 IV Days 1, 2, 3, Doxorubicin 25 mg/m\\^2 IV Day 1, Cyclophosphamide 650 mg/m\\^2 IV Day 1, Procarbzine 100 mg/m\\^2 PO Days 1-7, Prednisone 40 mg/m\\^2 PO Days 1-14, Bleomycin 10u/m\\^2 IV Day 8, Vincristine 1.4 mg/m\\^2 IV Day 8, Q 21 Days x 6 cycles","id":"OG002","title":"PET-positive: BEACOPP Standard"}],"paramType":"NUMBER","populationDescription":"Eligible HIV-positive patients who had received any treatment were included in the adverse event summaries. Any CTCAE 4.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which deemed to be related to protocol treatment are included.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","type":"SECONDARY","unitOfMeasure":"Participants"}